Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating on July 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that highlight the potential of Eli Lilly & Co’s involvement in the GLP-1 receptor agonists (GLP-1RAs) market. A recent study published in JAMA indicates that the use of GLP-1RAs, such as semaglutide and tirzepatide, is linked with a reduced risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. This suggests that GLP-1RAs may offer neuroprotective and cerebrovascular benefits beyond their primary role in glycemic control.
Furthermore, the study’s findings are promising in light of upcoming results from Novo Nordisk’s Alzheimer’s trials, which could positively impact Eli Lilly’s stock if successful. Given Eli Lilly’s strong position in both the incretin and Alzheimer’s markets, there is potential for significant stock appreciation should these trials yield favorable outcomes. Risinger’s rating reflects the strategic advantage and growth potential that Eli Lilly holds in these therapeutic areas.
In another report released on July 18, Jefferies also reiterated a Buy rating on the stock with a $1,057.00 price target.